A multicenter retrospective survey of poisoning after consumption of products containing novel psychoactive substances from 2013 to 2014 in Japan

ABSTRACT

Background: In Japan, fatalities among patients who experienced an acute reaction following self-administration of novel psychoactive substances (NPS) have been more frequently reported since June 2014. Objective: This survey aimed to document and analyze trends in NPS consumption in emergency patients. Methods: We conducted a multicenter retrospective survey of patients who were transported to emergency facilities after consuming NPS-containing products between January 2013 and December 2014. Letters requesting participation were sent to 467 emergency facilities, and questionnaires were mailed to facilities that agreed to participate. Results: We surveyed 589 patients from 85 (18.2%) facilities. Most patients were male (89.6%) and young (median age, 30 years), and inhaled (88%) NPS contained in herbal products (80.5%). Harmful behavior was observed at the scene of acute reaction, including violence (6.9%), traffic accidents (4.9%), and self-injury or suicidal attempts (1.1%). Other than neuropsychiatric and physical symptoms, many patients also had physical complications such as rhabdomyolysis (17.5%), liver injury (12.4%), acute kidney injury (9%), and physical injury (1.9%). Of the 256 patients (43.5%) admitted to hospitals, 35 (5.9%) were hospitalized for seven or more days. Most patients (93.2%) completely recovered, although a few (1.4%) died. However, synthetic cannabinoids and synthetic cathinones were only detected in the blood of five patients. Conclusion: Consumption of NPS-containing products have been associated with harmful behaviors such as violence and traffic accidents, physical complications (e.g., rhabdomyolysis, liver injury), death, or physical and neuropsychiatric symptoms. Compared to a previous survey (2006–2012), the present survey revealed more severe toxicity.

KEYWORDS:

• Acute kidney injury
• liver injury
• rhabdomyolysis
• synthetic cannabinoid
• synthetic cathinone

Acknowledgments

We thank the 60 participating emergency facilities for providing data.

Funding

This study was supported by a Grant-in-Aid for study of evaluation and management of new psychoactive substances, a cross-disciplinary study among psychiatry, emergency medicine, and forensic medicine (Principle Investigator, Toshihiko Matsumoto) from the Japan Agency for Medical Research and Development (AMED).

Supplemental data for this article can be accessed on the publisher’s website.

Additional information

Funding

This study was supported by a Grant-in-Aid for study of evaluation and management of new psychoactive substances, a cross-disciplinary study among psychiatry, emergency medicine, and forensic medicine (Principle Investigator, Toshihiko Matsumoto) from the Japan Agency for Medical Research and Development (AMED).